Cargando…
Prevalence of inverse psoriasis subtype with immune checkpoint inhibitors
BACKGROUND: Cutaneous immune-related adverse events (irAEs) are the most common irAEs caused by immune-checkpoint inhibitors (ICI). Psoriasiform eruptions, both de novo and flares, may occur. Evidence is lacking on inverse psoriasis subtype. METHODS: A retrospective study was conducted at Dana-Farbe...
Autores principales: | Jfri, Abdulhadi, Leung, Bonnie, Said, Jordan T, Semenov, Yevgeniy, LeBoeuf, Nicole R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525015/ https://www.ncbi.nlm.nih.gov/pubmed/36196370 http://dx.doi.org/10.1093/immadv/ltac016 |
Ejemplares similares
-
Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI)
por: Hanna, Glenn J., et al.
Publicado: (2020) -
Neighborhood characteristics and the risk of psoriasis: A systematic review
por: Luo, Owen Dan, et al.
Publicado: (2023) -
Risk of COVID‐19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors
por: Klebanov, Nikolai, et al.
Publicado: (2021) -
Disseminated varicella-zoster virus infections following messenger RNA–based COVID-19 vaccination
por: Said, Jordan Taylor, et al.
Publicado: (2021) -
Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
por: Halle, Briana Rose, et al.
Publicado: (2021)